Dyne Therapeutics, Inc. DYN Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Product | ||||||
| DYNE-101DM1 | $114.43M-21.1% | $145.08M+4.4% | $139M+5.2% | $132.07M+18.9% | $111.1M+50.0% | |
| DYNE-251DM1 | $115.59M+16.8% | $98.93M-2.1% | $101.08M-5.9% | $107.43M+7.9% | $99.58M+10.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Dyne Therapeutics, Inc. break its business down?
- Dyne Therapeutics, Inc. (DYN) reports research and development expense by product across 2 parts — DYNE-101DM1 and DYNE-251DM1. Each is extracted from the segment footnotes and tracked over time.
- Where does Dyne Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Dyne Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.